目的探讨窄带成像（narrow band imaging，NBI）内镜在喉癌及其癌前病变诊断中的应用价值。方法自2008年12月至2009年7月对122例怀疑有喉癌或癌前病变的患者选用具有普通白光和NBI两种观察模式的电子内镜进行咽喉部的检查。对发现的病...目的探讨窄带成像（narrow band imaging，NBI）内镜在喉癌及其癌前病变诊断中的应用价值。方法自2008年12月至2009年7月对122例怀疑有喉癌或癌前病变的患者选用具有普通白光和NBI两种观察模式的电子内镜进行咽喉部的检查。对发现的病灶依次使用白光和NBI模式进行分类和病灶性质的判断，以病理诊断作为金标准，比较两种观察模式对喉癌的诊断作用。结果122例患者中共发现了149个病灶，其中息肉16个，炎性反应7个，单纯性增生24个，轻度不典型增生17个，中度不典型增生6个，重度不典型增生6个，原位癌9个，浸润癌64个。NBI内镜对喉部病变的正确诊断率是90．6％（135／149），高于普通白光内镜的75．2％（112／149），两者比较差异有统计学意义（χ2=12．514，P〈0．001）。NBI内镜对喉癌诊断的敏感性为93．2％（68／73），高于普通白光内镜的68．5％（50／73，χ2=14．317，P〈0．001）。结论NBI内镜通过识别黏膜表面微细血管形态变化提高对喉癌诊断的敏感性和喉部病变诊断的正确率，从而增强内镜在喉癌术前诊断和术后随访中的作用。展开更多
Objective This review discusses the current status and progress in studies on gastric cancer with liver metastasis （GCLM）, involving the routes, subtypes, and prognosis of GCLM; the genes and molecules associated wi...Objective This review discusses the current status and progress in studies on gastric cancer with liver metastasis （GCLM）, involving the routes, subtypes, and prognosis of GCLM; the genes and molecules associated with metastasis;the feasibility and value of each imaging modality; and current treatment options.Data sources The data used in this review were mainly from Medline and PubMed published in English from 2005 to August 2010. The search terms were ＂gastric cancer＂ and ＂liver metastasis＂.Study selection Articles regarding the characteristics, diagnostic modalities, and vadous therapeutic options of GCLM were selected.Results The prognosis of GCLM is influenced by the clinicopathological characteristics of primary tumors, as well as the presence of liver metastases. Improved understanding of related genes and molecules will lead to the development of methods of early detection and targeted therapies. For the diagnosis of GCLM, each imaging modality has its relative benefits. There remains no consensus regarding therapeutic options.Conclusions Early detection and characterization of liver metastases is crucial for the prognosis of gastric cancer patients. Multidisciplinary team discussions are required to design optimal treatment strategies, which should be based on the clinicopathological characteristics of each patient.展开更多
文摘目的探讨窄带成像（narrow band imaging，NBI）内镜在喉癌及其癌前病变诊断中的应用价值。方法自2008年12月至2009年7月对122例怀疑有喉癌或癌前病变的患者选用具有普通白光和NBI两种观察模式的电子内镜进行咽喉部的检查。对发现的病灶依次使用白光和NBI模式进行分类和病灶性质的判断，以病理诊断作为金标准，比较两种观察模式对喉癌的诊断作用。结果122例患者中共发现了149个病灶，其中息肉16个，炎性反应7个，单纯性增生24个，轻度不典型增生17个，中度不典型增生6个，重度不典型增生6个，原位癌9个，浸润癌64个。NBI内镜对喉部病变的正确诊断率是90．6％（135／149），高于普通白光内镜的75．2％（112／149），两者比较差异有统计学意义（χ2=12．514，P〈0．001）。NBI内镜对喉癌诊断的敏感性为93．2％（68／73），高于普通白光内镜的68．5％（50／73，χ2=14．317，P〈0．001）。结论NBI内镜通过识别黏膜表面微细血管形态变化提高对喉癌诊断的敏感性和喉部病变诊断的正确率，从而增强内镜在喉癌术前诊断和术后随访中的作用。
基金This study was supported by the National Basic Science and Development Program （863 program No. 2006AA02A402） and National Natural Science Foundation of China （No. 30872468）.
文摘Objective This review discusses the current status and progress in studies on gastric cancer with liver metastasis （GCLM）, involving the routes, subtypes, and prognosis of GCLM; the genes and molecules associated with metastasis;the feasibility and value of each imaging modality; and current treatment options.Data sources The data used in this review were mainly from Medline and PubMed published in English from 2005 to August 2010. The search terms were ＂gastric cancer＂ and ＂liver metastasis＂.Study selection Articles regarding the characteristics, diagnostic modalities, and vadous therapeutic options of GCLM were selected.Results The prognosis of GCLM is influenced by the clinicopathological characteristics of primary tumors, as well as the presence of liver metastases. Improved understanding of related genes and molecules will lead to the development of methods of early detection and targeted therapies. For the diagnosis of GCLM, each imaging modality has its relative benefits. There remains no consensus regarding therapeutic options.Conclusions Early detection and characterization of liver metastases is crucial for the prognosis of gastric cancer patients. Multidisciplinary team discussions are required to design optimal treatment strategies, which should be based on the clinicopathological characteristics of each patient.
